CompoAtlas

MFIII SWISSPE SOFTGELS

MFIII SWISSPE SOFTGELS : Product registered in Malaysia. This registration does not constitute authorisation for sale in France or the European Union. It does not demonstrate the safety or efficacy of the product.

NPRA, Malaysian pharmaceutical products register, retrieved 27 October 2026.

Ministry of Health Malaysia / NPRA, Pharmaceutical Products, CC BY 4.0

CC BY 4.0

The foreign register category does not determine the regulatory category of the product in France.

French and European references for recognised ingredients

No point flagged by the rules applied to recognised ingredients.

Unidentified ingredients are not assessed. The absence of a signal does not establish product compliance.

Published composition

Published ingredientPublished text and quantityIdentified nutrient or substance
SHEEP PLACENTA CONCENTRATESHEEP PLACENTA CONCENTRATE[300.00 mg,1888.10 mg]Not identified
Pyrroloquinoline quinone disodium saltPyrroloquinoline quinone disodium salt[11.40 mg,1888.10 mg]Not identified
UBIQUINOLUBIQUINOL[31.25 mg,1888.10 mg]Ubiquinol
PROTEIN-MARINEPROTEIN-MARINE[200.00 mg,1888.10 mg]Not identified
QUERCETIN DIHYDRATEQUERCETIN DIHYDRATE[31.58 mg,1888.10 mg]Not identified
BORAGO OFFICINALIS (BORAGE OIL)BORAGO OFFICINALIS (BORAGE OIL)[681.17 mg,1888.10 mg]Not identified

The imported data provide no usable daily dosage. No daily dose is estimated and no comparison with dose limits is performed. A published quantity may refer to a preparation or an unspecified unit. Chinese names are retained without translation.

Product record

Registration number
MAL25026073NCR
Type
Health supplement
Published status
PRODUCT APPROVED
Licence holder
Superb Health Care Sdn Bhd
Manufacturer
GELPELL AG
Importer
Superb Health Care Sdn Bhd
Registration period starting
2025-02-04
Published validity end
2030-02-04

Original register data

View published fields and their variants
Active ingredients
SHEEP PLACENTA CONCENTRATE[300.00 mg,1888.10 mg],Pyrroloquinoline quinone disodium salt[11.40 mg,1888.10 mg],UBIQUINOL[31.25 mg,1888.10 mg],PROTEIN-MARINE[200.00 mg,1888.10 mg],QUERCETIN DIHYDRATE[31.58 mg,1888.10 mg],BORAGO OFFICINALIS (BORAGE OIL)[681.17 mg,1888.10 mg]
Valid until
2030-02-04
Registration date
2025-02-04
Published description
HEALTH SUPPLEMENT
Licence holder
Superb Health Care Sdn Bhd
Importer
Superb Health Care Sdn Bhd
Producer
GELPELL AG
Published name
MFIII SWISSPE SOFTGELS
Published reference
2024110416379N
Registration number
MAL25026073NCR
Published status
PRODUCT APPROVED

Official source

View the official register, number MAL25026073NCR

Ministry of Health Malaysia / NPRA, Pharmaceutical Products, CC BY 4.0

CC BY 4.0

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • UBIQUINOL
    Read the warning, when it applies and the studies cited

    UBIQUINOL

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Langsjoen and Langsjoen 2008; Rosenfeldt et al. 2007; Engelsen et al. 2003; Singh et al. 1999; Landbo and Almdal 1998; Spigset 1994).

    Sources cited by Health Canada (6)
    • Engelsen J, Nielsen JD, Hansen KF. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
    • Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
    • Langsjoen PH, Langsjoen AM. Supplemental ubiquinol in patients with advanced congestive heart failure. Biofactors 2008;32(1-4):119-128. PubMed Clinical trial
    • Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
    • Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial
    • Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report

    Applies to products providing more than 100 mg of Ubiquinol, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Langsjoen and Langsjoen 2008; Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).

    Sources cited by Health Canada (4)
    • Engelsen J, Nielsen JD, Hansen KF. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
    • Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
    • Langsjoen PH, Langsjoen AM. Supplemental ubiquinol in patients with advanced congestive heart failure. Biofactors 2008;32(1-4):119-128. PubMed Clinical trial
    • Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report

    Condition of application: Migraine prophylaxis/prevention.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.

    Health Canada monograph dated 30 January 2026

They concern the ingredient, not this product or its dose. They do not replace medical advice.

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “MFIII SWISSPE SOFTGELS”, https://compoatlas.com/en/supplements/malaysia/MAL25026073NCR-mfiii-swisspe-softgels, updated 27 October 2026.

Enter to analyse, Shift+Enter for a new line